Document Detail


Creatine kinase-BB in the cerebrospinal fluid as a marker of CNS metastases and leptomeningeal carcinomatosis in patients with breast cancer.
MedLine Citation:
PMID:  2632253     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
To determine whether creatine kinase-BB isoenzyme would be useful in detecting central nervous system metastases secondary to breast cancer, we measured the cerebrospinal fluid (CSF) activity of creatine kinase (CK) and its BB isoenzyme (CK-BB) in 65 consecutive patients suspected of having CNS involvement. All patients underwent neurological evaluation, computer tomography (CT) scan and/or radionuclide scintigraphy and lumbar puncture with CSF examination. Thirty patients had CNS metastases, of whom 18 had parenchymal brain metastases (MET). Twelve had leptomeningeal carcinomatosis (MC), of whom four also had parenchymal brain metastases. Thirty-four patients were concluded not to have CNS involvement, whereas one was considered equivocal. CK-BB activity was significantly higher in patients with CNS metastases than in those without (P less than 0.05). This difference was primarily related to the fact that patients with MC had a significantly higher CK-BB activity than patients without CNS metastases or patients with parenchymal brain metastases only (P less than 0.01 and P less than 0.05, respectively). Taking 0.20 U/l as a tentative cut-off value (the upper limit range of patients without CNS metastases being 0.19 U/l), 10 out of 12 patients with MC had activities above this level. The sensitivity and specificity for having MC were 83% and 87%, and the positive and negative predictive values 60% and 96%, respectively. The sensitivity and negative predictive value for having any CNS metastases were 57% and 72%. Specificity and positive predictive value: 100%. The CSF activity of CK-BB appears to be a contribution in the diagnosis of MC secondary to breast cancer and seems superior to protein and LDH.
Authors:
F Bach; F W Bach; A G Pedersen; P M Larsen; P Dombernowsky
Related Documents :
1950643 - Tumor marker determinations.
16145993 - Estimation of ca 125 concentration in patients with congestive heart failure.
17318713 - Evaluation of csf-chlamydia pneumoniae, csf-tau, and csf-abeta42 in alzheimer's disease...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European journal of cancer & clinical oncology     Volume:  25     ISSN:  0277-5379     ISO Abbreviation:  Eur J Cancer Clin Oncol     Publication Date:  1989 Dec 
Date Detail:
Created Date:  1990-05-24     Completed Date:  1990-05-24     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8112045     Medline TA:  Eur J Cancer Clin Oncol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  1703-9     Citation Subset:  IM    
Affiliation:
Department of Oncology, University Hospital Herlev, Copenhagen, Denmark.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Brain Neoplasms / cerebrospinal fluid,  diagnosis,  secondary*
Breast Neoplasms / cerebrospinal fluid*
Carcinoma / cerebrospinal fluid,  diagnosis,  secondary*
Creatine Kinase / cerebrospinal fluid*
Humans
Isoenzymes
Meningeal Neoplasms / cerebrospinal fluid,  diagnosis,  secondary*
Predictive Value of Tests
Tumor Markers, Biological / cerebrospinal fluid*
Chemical
Reg. No./Substance:
0/Isoenzymes; 0/Tumor Markers, Biological; EC 2.7.3.2/Creatine Kinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Blood flow distribution within transplantable tumours in the mouse.
Next Document:  Alcohol and breast cancer: update from an Italian case-control study.